|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
It is hard to see much growth in the market overall, until earnings growth returns.
Checking the gauges for underperformance, none of them look good.
Pfizer (PFE) has reportedly approached San Francisco based cancer drug maker Medivation (MDVN) about a buyout.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
Medivation is surging as Wall Street scouts the Big Pharma front for discounted M&A opportunities.
With hacking and cyber security making headlines, Jim Cramer recommended a few cyber security stocks for investors, including Palo Alto Networks (PANW), Fortinet (FTNT), FireEye (FEYE), and Cyberark Software (CYBR).
Shire's purchase of ViroPharma is a signal of deals and higher prices ahead, says Jason Kolbert, Sr. Research Analyst at the Maxim Group.
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Motivated CEOs, innovative products and smart deals count more than macro events.